Tc Biopharm Plc Stock Today
| TCBPW Stock | USD 0.01 0 8.89% |
PerformanceOK
| Odds Of DistressHigh
|
TC BioPharm is selling for under 0.0147 as of the 26th of February 2025; that is 8.89 percent up since the beginning of the trading day. The stock's lowest day price was 0.0139. TC BioPharm has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 1st of June 2024 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of February 2022 | Category Healthcare | Classification Health Care |
TC Biopharm Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Tc Biopharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. More on TC BioPharm plc
Moving against TCBPW Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
TCBPW Stock Highlights
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TC BioPharm can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand TC BioPharm's financial leverage. It provides some insight into what part of TC BioPharm's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TC BioPharm plc (TCBPW) is traded on NASDAQ Exchange in USA. It is located in Maxim 1, Motherwell, United Kingdom, ML1 4WR and employs 41 people. TC BioPharm is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
TC BioPharm plc has accumulated about 1.55 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check TC BioPharm Probability Of Bankruptcy
TC BioPharm Historical Income Statement
TCBPW Stock Against Markets
TC BioPharm Corporate Management
| Michael MBA | CoFounder Chairman | Profile | |
| Lauren Bor | Head Division | Profile | |
| Martin Thorp | CFO Director | Profile | |
| Christopher Camarra | Executive Communications | Profile | |
| Bryan Kobel | CEO Director | Profile | |
| Angela Scott | CoFounder COO | Profile |
Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.